Eli Lilly Shares Climb After Late-Stage Retatrutide Trial Shows Deep Weight Loss
Eli Lilly's stock moved higher in premarket trade after the company released results from a late-stage study of retatrutide, an investigational obesity therapy. At the top 12-milligram dose, participants without diabetes lost an average of 28.3% of body weight over 80 weeks, with over 45% achieving at least 30% weight loss. The data are positioned …